论文部分内容阅读
目的分析前列腺腺癌组织中C-myc和CyclinE的表达情况并探讨其临床意义。方法应用免疫组织化学及HE染色法检测80例前列腺腺癌组织和80例良性前列腺增生组织中C-myc和CyclinE的表达水平,并分析二者表达水平和前列腺腺癌临床病理参数的关系。结果前列腺腺癌中C-myc和CyclinE阳性率为67.5%和71.25%,良性前列腺增生组织中C-myc和CyclinE阳性率为22.50%和20%,差异均有统计学意义(P<0.05);C-myc在前列腺腺癌的肿瘤分化程度和临床分期差异均具有统计学意义(P<0.05),CyclinE在前列腺腺癌的肿瘤分化程度(P<0.05),但CyclinE在前列腺腺癌的临床分期差异无统计学意义(P>0.05)。结论 C-myc和CyclinE在前列腺腺癌与良性前列腺增生中的表达差异可能是前列腺腺癌发生发展的分子基础,二者的联合检测对前列腺腺癌预后的判断有指导作用。
Objective To analyze the expression of C-myc and CyclinE in prostatic adenocarcinoma and to investigate its clinical significance. Methods Immunohistochemistry and HE staining were used to detect the expression of C-myc and CyclinE in 80 cases of prostatic adenocarcinoma and 80 cases of benign prostatic hyperplasia. The relationship between the expression of C-myc and CyclinE and the clinicopathological parameters was analyzed. Results The positive rates of C - myc and CyclinE in prostatic adenocarcinoma were 67.5% and 71.25%, respectively. The positive rates of C - myc and CyclinE in benign prostatic hyperplasia tissues were 22.50% and 20% respectively, with statistical significance (P <0.05). The difference of tumor differentiation degree and clinical stage of C-myc in prostate adenocarcinoma was statistically significant (P <0.05), CyclinE was significantly higher in prostate adenocarcinoma (P <0.05), but CyclinE was positively correlated with clinical stage The difference was not statistically significant (P> 0.05). Conclusion The discrepancy between C-myc and CyclinE in prostatic adenocarcinoma and benign prostatic hyperplasia may be the molecular basis of the development of prostatic adenocarcinoma. The combined detection of prostatic carcinoma and benign prostatic hyperplasia may play a guiding role in judging the prognosis of prostatic adenocarcinoma.